neutral
Recently
Perspective Therapeutics posts wider loss in latest quarter
Perspective Therapeutics reported a wider quarterly loss as investors monitor revenue traction and clinical progress in a cautious biotech environment.
US based Perspective Therapeutics reported a quarterly loss of $0.29 per share, wider than market expectations, reflecting continued investment in clinical development. Revenue estimates stood near $283.9 million, highlighting early stage commercial traction. Investors are closely tracking cash burn and trial progress as the company advances its targeted alpha therapy pipeline amid heightened scrutiny in biotech markets.